

## **Astellas Announces Director Candidates after the Transition to a Company with an Audit & Supervisory Committee**

TOKYO, April 26, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) announced that, at a meeting of the Board of Directors held today, it decided on the following candidates for Directors (excluding Directors who are Audit & Supervisory Committee Members) and Directors who are Audit & Supervisory Committee Members to be elected at the Company’s 13th Term Ordinary General Meeting of Shareholders scheduled on June 15, 2018. The aforementioned candidates will assume office after the transition to a company with an Audit & Supervisory Committee.

With regard to the transition to a company with an Audit & Supervisory Committee from a company with an Audit & Supervisory Board, the Company has announced the information in the press release issued on January 31, 2018.

### 1. Candidates for Directors (excluding Directors who are Audit & Supervisory Committee Members)

Name	New Position	Current Position
Yoshihiko Hatanaka	Representative Director, Chairman of the Board	Same as on the left
Kenji Yasukawa	Representative Director, President and CEO	Same as on the left
Yoshiharu Aizawa	Outside Director	Same as on the left
Mamoru Sekiyama	Outside Director	Same as on the left
Keiko Yamagami	Outside Director	Same as on the left

Note: The Representative Directors as well as Chairman, and President and CEO are scheduled to be appointed at a meeting of the Board of Directors after the conclusion of the aforementioned Ordinary General Meeting of Shareholders.

2. Candidates for Directors who are Audit & Supervisory Committee Members

Name	New Position	Current Position
Tomokazu Fujisawa	Director, Audit & Supervisory Committee Member (New candidate)	Audit & Supervisory Board Member (Full-time)
Hiroko Sakai	Director, Audit & Supervisory Committee Member (New candidate)	Audit & Supervisory Board Member (Full-time)
Hitoshi Kanamori	Outside Director, Audit & Supervisory Committee Member (New candidate)	Outside Audit & Supervisory Board Member
Noriyuki Uematsu	Outside Director, Audit & Supervisory Committee Member (New candidate)	Outside Audit & Supervisory Board Member
Hiroo Sasaki	Outside Director, Audit & Supervisory Committee Member (New candidate)	

3. Candidate for substitute Director who is an Audit & Supervisory Committee Member

Name	New Position	Current Position
Haruko Shibusmura	Substitute outside Director who is an Audit & Supervisory Committee Member	

4. Director and Audit & Supervisory Board Members to be retired

(1) Director

Name	Current Position
Etsuko Okajima	Outside Director

## (2) Audit & Supervisory Board Members

Name	Current Position
Tomokazu Fujisawa	Audit & Supervisory Board Member (Full-time)
Hiroko Sakai	Audit & Supervisory Board Member (Full-time)
Toshiko Oka	Outside Audit & Supervisory Board Member
Hitoshi Kanamori	Outside Audit & Supervisory Board Member
Noriyuki Uematsu	Outside Audit & Supervisory Board Member

Note: All Audit & Supervisory Board Members will retire from their position at the time the Company transitions to a company with an Audit & Supervisory Committee. Tomokazu Fujisawa, Hiroko Sakai, Hitoshi Kanamori, and Noriyuki Uematsu, are candidates for Directors who are Audit & Supervisory Committee Members.

### **About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

### **Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473